Claudio Carini,
MD, PhD, FRCPath, Global Head, Clinical Immunology & Biomarkers
Dr. Carini has a strong passion in the application of biomarkers in translational medicine and personalized healthcare. Dr. Carini is currently appointed Global Head of Clinical Immunology and Biomarkers” at Pfizer Inc. and holds a Hon. Faculty position at King’s College, School of Medicine, Univ. of London. Dr. Carini is a strong believer of open innovation networks, and in his roles he has been collaborating intensely with biotechnological, and diagnostic industries, SMEs, biobanks, clinicians, technology providers and information specialists to accelerate applied scientific research through public-private partnerships. His technical expertise resides most strongly in molecular profiling methods (genetics, transcriptomics, proteomics, metabolomics, bioinformatics), in analytical biomarker development, and applications in translational scientific research. His professional background is a mix of academia, pharmaceutical industry, applied research institute, university medical center. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and being involved into public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. While working globally he has contributed to over 200 projects in various phases of biomarker R&D. Claudio is a strong believer of open innovation networks, and in his roles he has been collaborating with several stakeholders to accelerate applied scientific research through public-private partnerships. His technical expertise resides most strongly in molecular profiling, analytical biomarker development, and applications in translational scientific research. Dr. Carini obtained his MD in Italy. Later, he earned the PhD in Immunology from the University College London (UCL), University of London and subsequently an FRCPath in Immunology from the Royal College of Pathologists, London and Specialists Diplomas for Clinical Immunology and Respiratory Medicine from the University of Rome. Previously Dr Carini held senior roles in several Pharma Companies (Wyeth, Novartis, Roche, Fresenius) and Faculty positions at Harvard, Johns Hopkins, UCL, and Rome Univ
Dr Carini is serving in several national and international scientific boards: F-NIH Biomarkers Consortium Inflammation/Immunology Steering Committee MRC, UK) “Inflammation/ Immunology Initiative - UK Rheumatoid Arthritis Consortium, Steering Committee MRC, (UK) “Stratified Medicine, SLE Consortium, Steering Committee Biomarkers Development Center, Amsterdam, NL, Advisory Board IMI, ABIRISK, European Union/EFPIA” Board of Directors The PML Consortium, Board of Directors
Publications Dr. Carini has over 200 publications in national and international peer reviewed journals. Dr. Carini has co-edited two books in the field of Personalized Medicine: Biomarkers in Drug Development: A handbook of practice, application and strategy, 2010 Clinical and Statistical Considerations in Personalized Medicine, 2014
Memberships He is also member of various national and international societies and has served as ad hoc reviewer for numerous scientific journals.
|
|